http://www.thedoctorslounge.net/rss/oncology.xmlhttp://swiv.eu/the-doctors-lounge-oncology_189.xml Add to your feed
Only women at very high risk for breast cancer experience a benefit according to a study published in the journal Cancer.
A gene expression signature clearly distinguishes Burkitt lymphoma from DLBCL, a critical distinction in diagnosis.
Breast cancer with a certain genetic mutation can have breast-sparing surgery but should consider hormonal treatments.
A new test could give hospitals with limited resources an affordable way to improve the outcome of ALL treatment.
This trial is among the first to combine a biologic agent with a conventional chemotherapy agent for ovarian cancer.
Inability to repair chromosomal damage caused by UV-B radiation increases risk of basal cell and squamous cell carcinomas.
A study featured in Gynecologic Oncology shows the superiority of intraperitoneal chemotherapy in advanced ovarian cancer.
Women with genetic variant that are taking tamoxifen were more likely to see their cancer return.
The FDA has approved Pfizer's Aromasin® for adjuvant treatment of early breast cancer in postmenopausal women.
NEJM reports that Herceptin® following standard chemotherapy significantly reduces the risk of disease recurrence.
If you want to help us build a new RSS feed from existing resources, not the form of an RSS feed published on the Web, you can send us a message. Lay out all the necessary information and your email address, we will keep you informed (e) of the process. Applications clearly out-about will be ignored.
Click on the address to select it. Click copy and then paste it into your preferred reader.